Slingshot members are tracking this event:

Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data
The newly published data documented in the paper also support the favorable safety profile of NKTR-214. The compound was well-tolerated in rodents and in non-human primates (NHPs). Importantly, these pre-clinical safety studies showed that NKTR-214 did not lead to hypotension or vascular leak syndrome at predicted clinical therapeutic doses.As documented in the new publication, in a pre-clinical tumor re-challenge study in an EMT6 mouse breast cancer model, dosing of NKTR-214 in combination with anti-CTLA-4 antibody resulted in durable and complete responses lasting up to 170 days (5.5 months). When tumor-free animals were re-challenged with the same tumors with no additional treatment, the complete responders demonstrated sustained vaccine-like resistance. These results suggest that NKTR-214 provides a complementary mechanism of immune activation when used concurrently with approved antibody therapies.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nktr-214, Favorable Safety Profile In Non-human Primate, Cd8-positive Effector T Cells, Cytokine, T Cell